<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CONTEXT: Delayed <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> causes permanent neurological deficits or <z:hpo ids='HP_0011420'>death</z:hpo> in at least 15% of patients following otherwise successful treatment for ruptured <z:hpo ids='HP_0004944'>intracranial aneurysm</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Decreased bioavailability of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> has been associated with the development of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To determine whether infusions of <z:chebi fb="95" ids="16301">nitrite</z:chebi> will prevent delayed <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN, SETTING, AND SUBJECTS: A total of 14 anesthetized cynomolgus monkeys had an autologous blood clot placed around the right middle cerebral artery </plain></SENT>
<SENT sid="4" pm="."><plain>Cerebral arteriography was performed before clot placement and on days 7 and 14 to assess vasospasm </plain></SENT>
<SENT sid="5" pm="."><plain>The study was conducted from August 2003 to February 2004 </plain></SENT>
<SENT sid="6" pm="."><plain>INTERVENTIONS: A 90-mg <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="95" ids="16301">nitrite</z:chebi> intravenous solution infused over 24 hours plus a 45-mg <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="95" ids="16301">nitrite</z:chebi> bolus daily (n = 3); a 180-mg <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="95" ids="16301">nitrite</z:chebi> intravenous solution infused over 24 hours (n = 3); or a control saline solution infusion (n = 8) </plain></SENT>
<SENT sid="7" pm="."><plain>Each was infused continuously for 14 days </plain></SENT>
<SENT sid="8" pm="."><plain>MAIN OUTCOME MEASURES: <z:chebi fb="95" ids="16301">Nitrite</z:chebi>, S-nitrosothiol, and methemoglobin levels in blood and cerebrospinal fluid and degree of arteriographic vasospasm </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: In control monkeys, mean (SD) cerebrospinal fluid <z:chebi fb="95" ids="16301">nitrite</z:chebi> levels decreased from 3.1 (1.5) micromol/L to 0.4 (0.1) micromol/L at day 7 and to 0.4 (0.4) micromol/L at day 14 (P = .03) </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 8 control monkeys developed significant vasospasm of the right middle cerebral artery, which was complicated by <z:hpo ids='HP_0001297'>stroke</z:hpo> and <z:hpo ids='HP_0011420'>death</z:hpo> in 1 animal </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="199" ids="26708">Sodium</z:chebi> <z:chebi fb="95" ids="16301">nitrite</z:chebi> infusions increased the <z:chebi fb="95" ids="16301">nitrite</z:chebi> and methemoglobin levels (&lt;2.1% of total <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>) in the blood and cerebrospinal fluid without evoking systemic <z:hpo ids='HP_0002615'>hypotension</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="95" ids="16301">Nitrite</z:chebi> infusion prevented development of vasospasm (no animals developed significant vasospasm; mean [SD] reduction in right middle cerebral artery area on day 7 after <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> of 8% [9%] in <z:chebi fb="95" ids="16301">nitrite</z:chebi>-treated monkeys vs 47% [5%] in saline-treated controls; P&lt;.001) </plain></SENT>
<SENT sid="13" pm="."><plain>There was a negative correlation between the concentration of <z:chebi fb="95" ids="16301">nitrite</z:chebi> in cerebrospinal fluid and the degree of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> (P&lt;.001) </plain></SENT>
<SENT sid="14" pm="."><plain>Pharmacological effects of <z:chebi fb="95" ids="16301">nitrite</z:chebi> infusion were also associated with the formation of S-nitrosothiol in cerebrospinal fluid </plain></SENT>
<SENT sid="15" pm="."><plain>There was no clinical or pathological evidence of <z:chebi fb="95" ids="16301">nitrite</z:chebi> toxicity </plain></SENT>
<SENT sid="16" pm="."><plain>CONCLUSION: <z:hpo ids='HP_0011011'>Subacute</z:hpo> <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="95" ids="16301">nitrite</z:chebi> infusions prevented delayed <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> in a primate model of <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> </plain></SENT>
</text></document>